<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01976962</url>
  </required_header>
  <id_info>
    <org_study_id>MD-13-03</org_study_id>
    <nct_id>NCT01976962</nct_id>
  </id_info>
  <brief_title>Functional MR-guided Stereotactic Body Radiation Therapy of Prostate Cancer</brief_title>
  <official_title>Functional MR-guided Stereotactic Body Radiation Therapy of Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CancerCare Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CancerCare Manitoba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To improve radiation therapy of prostate cancer, the investigators must be able to accurately&#xD;
      identify the tumour. By using advanced functional imaging techniques available on&#xD;
      state-of-the-art MRI scanners to clearly show the specific location of the tumour inside the&#xD;
      prostate, the investigators can use advanced radiation therapy techniques to specifically&#xD;
      target the tumor and control it with as few radiotherapy clinic visits as possible. This is&#xD;
      different than current techniques which treat the whole prostate gland to the same dose,&#xD;
      delivered over 7-8 weeks of daily radiotherapy visits. By increasing the radiation dose to&#xD;
      the active tumor while still maintaining adequate radiation dose to the rest of the prostate,&#xD;
      the investigators hope to better control prostate cancer and reduce complications to nearby&#xD;
      normal tissues.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project combines advances in functional imaging of prostate cancer and hypofractionation&#xD;
      through stereotactic body radiotherapy (SBRT), with an aim to improve tumour control and&#xD;
      reduce or maintain normal tissue complications. The strategy will make use of the combined&#xD;
      effectiveness of several functional imaging approaches to identify the dominant lesion(s)&#xD;
      within the prostate. An SBRT treatment plan will be designed which utilizes 5 fractions to&#xD;
      treat the entire prostate gland with an additional boost to the dominant lesion. The lower&#xD;
      dose to the entire prostate should reduce normal tissue complications but still be effective&#xD;
      in treating prostate cancer while the increased dose to the dominant lesion should improve&#xD;
      tumour control. The use of only 5 fractions will reduce the number of patient visits, thus&#xD;
      reducing overall treatment costs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life as per EPIC</measure>
    <time_frame>6 months</time_frame>
    <description>Expanded Prostate Cancer Index Composite (EPIC) bowel domain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as per EPIC and SF-12</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Expanded Prostate Cancer Index Composite (EPIC) questionnaire (other domains) and Medical Outcomes Study Short-Form 12 (SF-12) v2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GU and GI Toxicity</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>RTOG and CTCAE v4.0 genitourinary and gastrointestinal toxicities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical failure</measure>
    <time_frame>5 years</time_frame>
    <description>Phoenix defined (nadir PSA + 2 ng/mL) biochemical failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic response</measure>
    <time_frame>3 years</time_frame>
    <description>Pathologic presence of malignancy on biopsy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">77</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Prostate stereotactic body RT with MR-guided boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a dose of 36.25 Gy in 5 fractions to the entire prostate and proximal seminal vesicles with an additional boost to the dominant lesion for a total of 40 Gy in 5 fractions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic body RT with MR-guided boost</intervention_name>
    <description>Patients will receive radiotherapy over 5 fractions delivered once per week over 29 days, with 7.25 Gy per fraction to the whole prostate and 8 Gy per fraction to the dominant intraprostatic lesion. There will be a minimum of 120 hours and maximum of 192 hours between fractions. The entire course of treatment should be completed within no less than 27 days and no longer than 30 days.</description>
    <arm_group_label>Prostate stereotactic body RT with MR-guided boost</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Histologically confirmed and centrally reviewed prostate adenocarcinoma based&#xD;
&#xD;
          -  PSA within 60 days&#xD;
&#xD;
          -  High risk prostate cancer defined as any one of: clinical stage &gt;= T3, Gleason score&#xD;
             &gt;= 8, or PSA &gt;=20 and &lt;50 ng/mL.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of lymph node metastasis&#xD;
&#xD;
          -  Evidence of distant metastases&#xD;
&#xD;
          -  Prior pelvic radiotherapy or brachytherapy&#xD;
&#xD;
          -  Previous radical prostatectomy, cryotherapy, or high-frequency ultrasound&#xD;
&#xD;
          -  Unable to undergo gold seed insertion&#xD;
&#xD;
          -  Immunosuppressive medications&#xD;
&#xD;
          -  Inflammatory bowel disease&#xD;
&#xD;
          -  Unable to undergo MRI&#xD;
&#xD;
          -  Previous bilateral orchiectomy&#xD;
&#xD;
          -  Previous hormonal therapy including LHRH agonists (leuprolide, goserelin), LHRH&#xD;
             antagonists (degarelix), anti-androgens (bicalutamide, flutamide, nilutamide),&#xD;
             surgical castration, and estrogens&#xD;
&#xD;
          -  Previous finasteride within 14 days.&#xD;
&#xD;
          -  Previous dutasteride within 180 days.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aldrich Ong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CancerCare Manitoba</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aldrich Ong, MD</last_name>
    <phone>(204) 787-2116</phone>
    <email>aong3@cancercare.mb.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lawrence Ryner, PhD</last_name>
    <phone>(204) 787-8537</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aldrich Ong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 25, 2013</study_first_submitted>
  <study_first_submitted_qc>October 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2013</study_first_posted>
  <last_update_submitted>February 19, 2019</last_update_submitted>
  <last_update_submitted_qc>February 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostatic neoplasms</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Dose fractionation</keyword>
  <keyword>Magnetic resonance imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

